<HashMap><database>bioimages</database><scores/><additional><omics_type>Unknown</omics_type><submitter>Gwennie Hoslett</submitter><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-BIAD3162</full_dataset_link><repository>bioimages</repository><figure_sub>Specimen</figure_sub><figure_sub>Funding</figure_sub><figure_sub>Study Component</figure_sub><figure_sub>Biosample</figure_sub><figure_sub>organisation</figure_sub><figure_sub>Associations</figure_sub><figure_sub>Image acquisition</figure_sub><pubmed_authors>Gwennie Hoslett</pubmed_authors></additional><is_claimable>false</is_claimable><name>Nucleophagy removes cytotoxic trapped PARP1</name><description>Poly (ADP-Ribose) Polymerase inhibitors (PARPi) induce cytotoxicity in homologous recombination repair (HRR)-deficient cancers by trapping PARP1 on chromatin, thereby causing irreparable replication-associated DNA damage. Although increased clearance of trapped PARP1 from chromatin reduces the sensitivity of cancer cells to PARPi, details surrounding this process remain unclear. PARPi exposure is known to cause increased autophagy flux, whilst autophagy inhibition can hypersensitise cells to PARPi. Our study reveals that trapped PARP1 is cleared via nucleophagy, with the selective autophagy receptor TEX264 and its partner segregase p97/VCP orchestrating this process. TEX264 interacts directly with trapped PARP1, linking it to the autophagosomal protein LC3 for degradation. Disrupting this pathway, either chemically or genetically, increases PARP1 trapping, resulting in protein aggregates, DNA damage, and cell lethality, ultimately re-sensitising PARPi-resistant cells. We conclude that nucleophagy serves a cytoprotective role by targeting PARPi-induced trapped PARP1 for degradation.</description><dates><release>2026-03-28T00:00:00Z</release><modification>2026-06-26T00:17:12.564Z</modification><creation>2026-03-28T22:03:06.081Z</creation></dates><accession>S-BIAD3162</accession><cross_references/></HashMap>